Dendreon Corporation (NASDAQ:DNDN), shares were down ever since it announced its first-quarter 2014 results on May 8. The stock has lost around 19.5% so far. Dendreon Corporation (NASDAQ:DNDN), weekly performance is -17.60%. On last trading day company shares ended up $2.06. Analysts mean target price for the company is $2.77. Dendreon Corporation (NASDAQ:DNDN), distance from 50-day simple moving average (SMA50) is -26.32%.
DARA Biosciences Inc (NASDAQ:DARA), announced its first quarter 2014 results. For the first quarter ended March 31, 2014, DARA reported a net loss attributable to controlling interest of ($2,658,081), or ($0.37) per share as compared to a net loss attributable to controlling interest of ($2,522,588), or ($0.55) per share for the first quarter ended March 31, 2013. As of March 31, 2014, cash and cash equivalents totaled $6,828,100. DARA Biosciences Inc (NASDAQ:DARA), fell 3.60% in last trading session and ended the day on $1.34. DARA, Gross Margin is 50.00% and its return on assets is -107.20%. DARA Biosciences Inc (NASDAQ:DARA), quarterly performance is -50.74%.
BioTime, Inc. (NYSEMKT:BTX), reported financial results for the first quarter ended March 31, 2014 and highlighted recent corporate accomplishments. Net loss attributable to BioTime for the three months ended March 31, 2014 was $8.1 million or $0.14 per share, compared to a net loss of $7.7 million or $0.15 per share for the same period in 2013. The increase in net loss is primarily attributed to increased research and development related activity in Asterias. This increase is to some extent offset by the $1.3 million income tax benefit recorded as of March 31, 2014 compared with none in the same period in 2013. BioTime, Inc. (NYSEMKT:BTX), shares moved up 10.64% in last trading session and was closed at $2.60, while trading in range of $ 2.21 – 2.67. BioTime, Inc. (NYSEMKT:BTX), year to date (YTD) performance is -27.78%.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), said first-quarter loss widened to $18.4 million from $8.2 million last year. On a per-share basis, earnings were $0.85, compared to $2.84 last year. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), ended the last trading day at $34.04. Company weekly volatility is calculated as 8.64% and price to cash ratio as 19.15. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), showed a negative weekly performance of -11.68%.
On May 08, 2014, Biota Pharmaceuticals Inc (NASDAQ:BOTA), in a press release announced that the company would no longer provide services of developing Laninamivir octanoate, to the government’s Biomedical Advanced Research and Development Authority (BARDA) and the Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response (ASPR). Biota Pharmaceuticals Inc (NASDAQ:BOTA), net profit margin is -19.60% and weekly performance is -13.25%. On last trading day company shares ended up $2.88. Analysts mean target price for the company is $7.00. Biota Pharmaceuticals Inc (NASDAQ:BOTA), distance from 50-day simple moving average (SMA50) is -48.19%.